A Study of Pembrolizumab (MK-3475) With or Without Intismeran Autogene (V940) in Participants With Non-small Cell Lung Cancer (V940-009/INTerpath-009)
NCT06623422
This study is recruiting at 50 US sites in 19 states, according to its ClinicalTrials.gov record last updated .
Summary
The goal of this study is to learn if people who receive intismeran autogene and pembrolizumab after surgery are cancer-free longer than people who receive placebo and pembrolizumab. Researchers want to know if giving intismeran autogene and pembrolizumab after surgery can help prevent the cancer from coming back in people with non-small cell lung cancer (NSCLC) whose tumors did not respond completely to treatment before surgery (neoadjuvant treatment).
Shortened from the sponsor's brief summary. View official record on ClinicalTrials.gov
Conditions studied
- Carcinoma, Non-Small-Cell Lung
Eligibility basics and study details
- Study type
- Interventional
- Phase
- Phase 3
- Ages
- 18 years and older
- Sex
- All
- Healthy volunteers
- Not accepted
- Sponsor
- Merck Sharp & Dohme LLC
- Last updated on ClinicalTrials.gov
- October 2, 2026
These are the basic criteria only. The full inclusion and exclusion criteria are on the official record, and the study team decides who can take part.
US recruiting sites
Arizona · 2
- Banner MD Anderson Cancer Center ( Site 0181) · Gilbert, AZ
- The University of Arizona Cancer Center - North Campus ( Site 0163) · Tucson, AZ
California · 5
- Providence St. Jude Medical Center ( Site 0106) · Fullerton, CA
- VA Long Beach Healthcare System ( Site 0199) · Long Beach, CA
- UCLA Jonsson Comprehensive Cancer Center ( Site 0135) · Los Angeles, CA
- USC Norris Comprehensive Cancer Center ( Site 0205) · Los Angeles, CA
- UCSF Medical Center at Mission Bay ( Site 0178) · San Francisco, CA
Colorado · 4
- University of Colorado Anschutz Medical Campus ( Site 0151) · Aurora, CO
- UCHealth Memorial Hospital Central ( Site 0125) · Colorado Springs, CO
- Banner MD Anderson Cancer Center at North Colorado Medical Center ( Site 0207) · Greeley, CO
- Centura Health - St. Anthony North Health Campus ( Site 0189) · Westminster, CO
Connecticut · 2
- Yale University School of Medicine ( Site 0201) · New Haven, CT
- Eastern CT Hematology & Oncology Associates ( Site 0202) · Norwich, CT
Florida · 2
- The Oncology Institute of Hope and Innovation - Fort Lauderdale ( Site 0156) · Fort Lauderdale, FL
- Miami Cancer Institute at Baptist Health, Inc. ( Site 0214) · Miami, FL
Idaho · 1
- Beacon Cancer Care ( Site 0127) · Post Falls, ID
Illinois · 1
- The University of Chicago Medical Center ( Site 0118) · Chicago, IL
Indiana · 1
- Franciscan Health ( Site 0219) · Indianapolis, IN
Maryland · 1
- Maryland Oncology Hematology (MOH) ( Site 8102) · Rockville, MD
Massachusetts · 2
- Dana Farber Cancer Hospital ( Site 0155) · Boston, MA
- Massachusetts General Hospital ( Site 0136) · Boston, MA
New York · 8
- Roswell Park Cancer Institute ( Site 0184) · Buffalo, NY
- Hematology-Oncology Associates of CNY ( Site 0164) · East Syracuse, NY
- Icahn School of Medicine at Mount Sinai ( Site 0116) · New York, NY
- Memorial Sloan Kettering Cancer Center ( Site 0137) · New York, NY
- The Blavatnik Family- Chelsea Medical Center at Mount Sinai ( Site 0216) · New York, NY
- SUNY Upstate Cancer Center ( Site 0140) · Syracuse, NY
- Montefiore Medical Center ( Site 0160) · The Bronx, NY
- Westchester Medical Center ( Site 0196) · Valhalla, NY
North Carolina · 2
- Novant Health Weisiger Cancer Insititute ( Site 0266) · Charlotte, NC
- Novant Health Forsyth Medical Center ( Site 0166) · Winston-Salem, NC
Ohio · 1
- University of Cincinnati Medical Center ( Site 0119) · Cincinnati, OH
Oregon · 1
- Good Samaritan Regional Medical Center-Samaritan Pastega Regional Cancer Center ( Site 0217) · Corvallis, OR
Pennsylvania · 1
- St. Lukes Hospital and Health Network ( Site 0186) · Bethlehem, PA
Tennessee · 3
- Tennessee Oncology, PLLC - Chattanooga Downtown ( Site 0315) · Chattanooga, TN
- Thompson Cancer Survival Center ( Site 0168) · Knoxville, TN
- Elliston Place Medical Oncology & Hematology ( Site 0215) · Nashville, TN
Texas · 8
- Texas Oncology - DFW ( Site 8103) · Dallas, TX
- UT Southwestern Medical Center ( Site 0190) · Dallas, TX
- Houston Methodist Cancer Center ( Site 0191) · Houston, TX
- MD Anderson Cancer Center ( Site 0150) · Houston, TX
- Memorial Hermann Cancer Center ( Site 0172) · Houston, TX
- Michael E. DeBakey VA Medical Center ( Site 0197) · Houston, TX
- O'Quinn Medical Tower at McNair Campus ( Site 0131) · Houston, TX
- The University of Texas Health Science Center at Tyler dba UT Health East Texas HOPE Cancer Center ( Site 0148) · Tyler, TX
Virginia · 3
- Virginia Cancer Specialists ( Site 0167) · Fairfax, VA
- Virginia Oncology Associates (VOA) ( Site 8101) · Norfolk, VA
- VCU Health Adult Outpatient Pavillion ( Site 0193) · Richmond, VA
Washington · 2
- Swedish Cancer Institute ( Site 0143) · Seattle, WA
- St. Joseph Medical Center Hematology and Oncology - Silverdale ( Site 0192) · Silverdale, WA
Source: ClinicalTrials.gov, data processed . Recruiting US sites filtered by distance and site status; summaries shortened.